Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss
- PMID: 15238112
- DOI: 10.1111/j.1447-0756.2004.00206.x
Antiphosphatidylethanolamine antibodies in recurrent early pregnancy loss and mid-to-late pregnancy loss
Abstract
Aim: Associations have been reported between antiphospholipid antibodies (aPL), mainly anticardiolipin antibodies (aCL) and/or the lupus anticoagulant, and recurrent pregnancy losses (RPL). However, relatively few studies describing antiphosphatidylethanolamine antibodies (aPE) have been reported. We describe the prevalence of aPL to both cardiolipin and phosphatidylethanolamine in patients with RPL.
Methods: Patients with recurrent early pregnancy losses (n = 145) and mid-to-late pregnancy loss(es) (n = 26) were screened for aPE and aCL.
Results: In patients with recurrent early pregnancy losses, prevalence of immunoglobulin G (IgG) aPE (17.9%, P = 0.001) and immunoglobulin M (IgM) aPE (12.4%, P = 0.01) was significantly higher than in the control group. In patients with mid-to-late pregnancy loss(es), prevalence of IgM aPE (19.2%, P = 0.008) and IgG aCL (23.1%, P = 0.02) was significantly higher than in the control group.
Conclusion: Our data suggest that aPE may be a risk factor in patients with mid-to-late pregnancy loss(es) as well as recurrent early pregnancy losses.
Similar articles
-
Antiphosphatidylethanolamine antibodies might not be an independent risk factor for further miscarriage in patients suffering recurrent pregnancy loss.J Reprod Immunol. 2010 Jun;85(2):186-92. doi: 10.1016/j.jri.2010.03.002. Epub 2010 May 11. J Reprod Immunol. 2010. PMID: 20462639
-
Antiphosphatidylethanolamine antibodies as the only antiphospholipid antibodies. I. Association with thrombosis and vascular cutaneous diseases.J Rheumatol. 1996 Aug;23(8):1369-74. J Rheumatol. 1996. PMID: 8856615
-
Prevalence and heterogeneity of antiphosphatidylethanolamine antibodies in patients with recurrent early pregnancy losses.Fertil Steril. 1999 Jun;71(6):1060-5. doi: 10.1016/s0015-0282(99)00119-3. Fertil Steril. 1999. PMID: 10360910
-
Clinical significance of antiphosphatidylethanolamine antibodies in the so-called "seronegative antiphospholipid syndrome".Autoimmun Rev. 2009 Dec;9(2):90-2. doi: 10.1016/j.autrev.2009.03.007. Epub 2009 Mar 20. Autoimmun Rev. 2009. PMID: 19306951 Review.
-
Antiphosphatidylethanolamine antibodies and the antiphospholipid syndrome.Lupus. 2009 Sep;18(10):920-3. doi: 10.1177/0961203309106920. Lupus. 2009. PMID: 19671793 Review.
Cited by
-
Is testing for antiphosphatidylethanolamine antibodies clinically useful?Curr Rheumatol Rep. 2011 Feb;13(1):81-5. doi: 10.1007/s11926-010-0147-5. Curr Rheumatol Rep. 2011. PMID: 21061099 Review.
-
Correlation of anti-phosphatidylethanolamine antibodies with premature birth in women with a history of miscarriage: a retrospective study.BMJ Open. 2025 Apr 27;15(4):e090323. doi: 10.1136/bmjopen-2024-090323. BMJ Open. 2025. PMID: 40288804 Free PMC article.
-
Detection of non-criteria autoantibodies in women without apparent causes for pregnancy loss.J Clin Lab Anal. 2019 Nov;33(9):e22994. doi: 10.1002/jcla.22994. Epub 2019 Aug 11. J Clin Lab Anal. 2019. PMID: 31402484 Free PMC article.
-
The outcome of ELISA for antiphosphatidylethanolamine antibodies is dependent on the composition of phosphatidylethanolamine.J Immunol Methods. 2017 Jan;440:27-34. doi: 10.1016/j.jim.2016.10.005. Epub 2016 Oct 23. J Immunol Methods. 2017. PMID: 27784626 Free PMC article.
-
Antiphospholipid syndrome in 2014: more clinical manifestations, novel pathogenic players and emerging biomarkers.Arthritis Res Ther. 2014;16(2):209. doi: 10.1186/ar4549. Arthritis Res Ther. 2014. PMID: 25166960 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous